Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE rejects infliximab treatment for subacute ulcerative colitis

  • Comment
The National Institute for Health and Clinical Excellence (NICE) has not recommended infliximab for subacute moderately to severely active ulcerative colitis.
NICE’s technology appraisal committee found that using infliximab in these circumstances did not offer value for money to the NHS.

Professor Peter Littlejohns, NICE clinical and public health director and executive lead for the appraisal, said: ‘The committee concluded that the technology could not be considered a cost-effective use of NHS resources and so could not recommend its use.’

Later this year, NICE will publish guidance on the use of infliximab for the treatment of acute manifestations of the condition.

Ulcerative colitis is a disease that causes inflammation of the large intestine or colon and symptoms vary from pain and discomfort, mucus in stools and in severe cases, blood in stools.
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs